CorDx Secures Emergency Use Authorization For Its Rapid Flu A/B & COVID-19 Test

CorDx, a renowned name in the global biotechnology sector, has recently achieved a significant milestone by securing Emergency Use Authorization (EUA) for its innovative CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test. This advanced diagnostic tool is a lateral flow immunoassay designed for the qualitative detection and differentiation of nucleocapsid protein antigen from SARS-CoV-2, influenza type A, and influenza type B. The test, which delivers results in just 10 minutes, represents a significant advancement in the ability to diagnose and distinguish between these respiratory viruses efficiently.

The CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test is intended for professional use and can be administered by healthcare professionals or trained individuals in patient-care settings. It utilizes nasal swab samples from individuals suspected of respiratory viral infections, providing a quick and reliable diagnostic solution. This 3-in-1 multiplex test is particularly crucial as the world continues to navigate the challenges posed by influenza and COVID-19, offering a rapid diagnostic capability at the point-of-care (POC).

Despite its current authorization for POC use under an EUA, CorDx is optimistic about receiving over-the-counter (OTC) authorization in the future. This would further enhance accessibility to rapid testing for families and communities, emphasizing the importance of health prioritization. Aiiso Li, Founder and Chief Scientific Officer of CorDx, expressed satisfaction with the EUA achievement and highlighted the potential impact of OTC authorization on public health.

CorDx stands at the forefront of the diagnostics industry, offering innovative research and development solutions that have transformed global diagnostics. With a vertically integrated supply chain and manufacturing capabilities in the United States and internationally, CorDx is committed to developing, manufacturing, and distributing diagnostic tools that are not only affordable and user-friendly but also precise. The organization's proprietary diagnostic solutions have garnered recognition from both families and medical professionals worldwide.

For those interested in learning more about the CorDx Tyfast Flu A/B & COVID-19 Multiplex Rapid Test or exploring distribution opportunities, further information can be found on the official CorDx website.

In an era where rapid and accurate diagnosis of respiratory viruses is more critical than ever, CorDx's latest achievement marks a significant step forward in healthcare diagnostics. The availability of such advanced testing methods is essential for labs and healthcare providers striving to offer efficient diagnostic solutions amidst the ongoing surge of respiratory viruses.